Aspen Pharmacare will become a major African supplier of Merck’s experimental monthly HIV prevention pill, alimatravir. The agreement depends on the medicine successfully completing clinical trials and receiving regulatory approval. Merck granted voluntary licenses to seven generic drug manufacturers, including the South African company, to produce and distribute lower-cost versions of the medicine. The drug also goes by its development…
Tag: Access to Medicines
-
Lenacapavir Access Under Scrutiny by Health Advocates
A global coalition of health advocates is intensifying its campaign against pharmaceutical giant Gilead Sciences. They demand equitable access to its revolutionary long-acting injectable HIV prevention drug, lenacapavir. Activists are calling for a universal generic price of $40 per person per year for all low and middle-income countries. They warn that Gilead’s current policies entrench life-threatening inequities in the global…